Saiwon Healthcare Launches Free Neuropathy Screening Programme in Kerala
KOCHI, KERALA (March 1, 2024) – In response to the overwhelming success of our BMD camps, Saiwon Healthcare (INDIA) is proud to announce a new Corporate Social Responsibility (SCSR) initiative: “ Free neuropathy screening tests for the public ”. This program will be available starting from March 2024 and aims to facilitate in improving early detection of neuropathy.
which is a common complication of diabetes, and as a state , Kerala faces a concerning rise in diabetic peripheral neuropathy cases. This condition can lead to severe pain, numbness, and in the worst cases, amputation. Saiwon Healthcare's program will help to identify neuropathy early, allowing for timely intervention and improved outcomes.
“We at SAIWON are committed to improving the health and well-being of our communities,” said the Chairman and Managing Director of Saiwon Healthcare (INDIA) . “Early detection of neuropathy " is crucial in preventing serious complications. We are also proud to introduce Our brand MECOWONTIN, which is a groundbreaking combination of drugs added with a NOVEL DRUG DELIVERY TECHNOLOGY for the treatment of neuropathic disorders, offering pain relief and promoting neuro-regeneration.",
in neuropathic disorders MECOWONTIN is a technologically advanced brand for “ Demoting pain and promoting neuro regeneration ". .
Saiwon Healthcare (INDIA) , is a rapidly expanding pharmaceutical company establishing itself as a force within the industry. With a dedication to innovation, Saiwon Healthcare focuses on developing cutting-edge pharmaceutical products to meet the evolving needs of patients. The company's commitment to research and development, coupled with its focus on producing high-quality and accessible medicines, positions Saiwon Healthcare as a key player in shaping the future of Indian healthcare.